Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) is now available.
Hangzhou Tigermed Consulting Co., Ltd. announced an update regarding its final cash dividend for the year ended December 31, 2024. The dividend, set at RMB 3 per 10 shares, will be paid on July 31, 2025, following shareholder approval on May 30, 2025. The announcement includes details on the withholding tax rates applicable to different categories of shareholders, with non-resident enterprises and individuals subject to a 10% tax and mainland individual investors facing a 20% tax. This update clarifies the default currency for dividend payment and emphasizes the company’s commitment to transparent financial practices, potentially impacting investor relations and market perception.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. operates in the consulting industry, providing clinical trial services and solutions primarily focused on the pharmaceutical and biotechnology sectors. The company is known for its comprehensive suite of services that support drug development and regulatory compliance, catering to a global market.
YTD Price Performance: -19.13%
Average Trading Volume: 121
Technical Sentiment Signal: Buy
Current Market Cap: €3.88B
For detailed information about 3347 stock, go to TipRanks’ Stock Analysis page.